Survivors of Hodgkin Lymphoma at Increased Risk for Head and Neck Cancer
the Cancer Therapy Advisor take:
Survivors of Hodgkin Lymphoma with squamous cell carcinoma (HL-SCC) are more likely to develop salivary and non salivary head and neck cancer (HNC) after HL than those patients with a first primary SCC, according to a journal article published online in Cancer.
Data from the Surveillance, Epidemiology, and End Results (SEER) database for 1973 through 2011 was used to analyze survivors of HL who developed HCN as a secondary malignancy. These patients were then compared with patients with first primary HCN.
Observed-to-expected ratios were calculated for SCC among patients with HL (1.73; 95% CI, 1.36-2.16; P<0.05) and for SGC (8.56; 95% CI, 5.82-12.15; P<0.05).
Patient history of HL was determined to be an adverse prognostic fact for patient survival for SCC (HR = 1.37; 95% CI: 1.08, 1.73; P=0.009) but not for SGC (HR = 1.21; 95% CI: 0.82, 1.79; P=0.34). Increased risk of mortality in patients with HL-SCC appears to be associated with the deaths from HL and secondary malignancies diagnosed after SCC.
The study suggests that survivors of HL should have regular head and neck examinations and clinicians should be aware of patients’ increased risk for developing HCN after HL.

Survivors of HL-SCC are more likely to develop salivary and non salivary head and neck cancer.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Opinion: Understanding the FDA's Take on Cannabidiol
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk